Dataset Information

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.

ABSTRACT: Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.

SUBMITTER: Cao X

PROVIDER: S-EPMC9476467 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.

Cao Xia X Maruyama Junki J Zhou Heyue H Fu Yanwen Y Kerwin Lisa L Powers Colin C Sattler Rachel A RA Manning John T JT Singh Alok A Lim Reyna R Healy Laura D LD Johnson Sachi S Paz Cabral Elizabeth E Li Donghui D Lu Lucy L Ledesma Arthur A Lee Daniel D Richards Susan S Rivero-Nava Laura L Li Yan Y Shen Weiqun W Stegman Karen K Blair Benjamin B Urata Shinji S Kishimoto-Urata Magumi M Ko Jamie J Du Na N Morais Kyndal K Lawrence Kate K Rivera Ianne I Pai Chin-I CI Bresson Damien D Brunswick Mark M Zhang Yanliang Y Ji Henry H Paessler Slobodan S Allen Robert D RD

Scientific reports 20220915 1

Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha ...[more]

PMID: 36109550

Similar Datasets

Project description:In the earliest days of the COVID-19 pandemic, the collection of dried blood spots (DBS) enabled public health laboratories to undertake population-scale seroprevalence studies used to estimate rates of SARS-CoV-2 exposure. With SARS-CoV-2 seropositivity levels now estimated to exceed 94% in the United States, attention has turned to using DBS to assess neutralizing antibodies within cohorts of interest. With this goal in mind, we generated contrived DBS (cDBS) and whole blood-derived DBS from convalescent and vaccinated individuals and subjected DBS eluates to a battery of assays, including a SARS-CoV-2 multiplexed microsphere immunoassay (MIA), a receptor binding domain (RBD)-human ACE2 inhibition assay (iACE2), a cell-based pseudovirus neutralization assay, and real-time PCR-based surrogate neutralization assay (NAB-Sure). The DBS results were benchmarked against paired serum samples tested in a clinically validated SARS-CoV-2 plaque reduction neutralization titer (PRNT) assay. The results of an 8-plex MIA and NAB-Sure assays demonstrated highly significant correlations with PRNT values when evaluated with a panel of 86 paired serum-DBS samples. Both the MIA and NAB-Sure are adaptable to automated liquid handlers for high-throughput capacity. While neutralizing assays were limited to the ancestral SARS-CoV-2 WA1, this study nonetheless represents an important proof of concept demonstrating the potential utility of DBS as a biospecimen type for use in assessing immunity to SARS-CoV-2 at the community and population levels.IMPORTANCESARS-CoV-2 variants of concern continue to circulate globally and remain a serious health threat to large segments of the population. From a public health standpoint, identifying vulnerable communities based on immune status is critical in terms of vaccine booster recommendations. In this report, we investigated the utility of dried blood spots (DBS) as a biospecimen type from which to estimate SARS-CoV-2 neutralizing antibody titers. Using contrived and whole blood-derived DBS, we demonstrate that SARS-CoV-2 neutralizing antibodies are readily measurable in DBS eluates and correlate with plaque reduction neutralization titer (PRNT) values from paired serum samples. Moreover, several of the methods used to estimate SARS-CoV-2 neutralizing antibodies in DBS eluates are adaptable to high-throughput platforms.

Dataset Information

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.

Publications

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets